Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Zynex Inc

Healthcare US ZYXI

NoneUSD
-(-%)

Last update at 2026-03-10T21:04:13.923545Z

Day Range

--
LowHigh

52 Week Range

1.6610.63
LowHigh

Fundamentals

  • Previous Close 0.09
  • Market Cap74.99M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.63000M
  • Revenue TTM172.40M
  • Revenue Per Share TTM5.43
  • Gross Profit TTM 134.26M
  • Diluted EPS TTM-0.24

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 22.20M 22.27M 10.15M 11.94M 10.22M
Minority interest - - - -0.08900M -0.08900M
Net income 17.05M 17.10M 9.07M 9.49M 9.55M
Selling general administrative 36.11M 26.32M 18.32M 11.58M 15.51M
Selling and marketing expenses 67.12M 54.29M 34.13M 14.02M -
Gross profit 126.16M 102.98M 62.70M 36.66M 25.88M
Reconciled depreciation 3.13M 2.29M 1.57M 0.78M 0.45M
Ebit 19.81M 20.08M 10.25M 10.29M 9.92M
Ebitda 22.94M 22.37M 11.74M 11.07M 10.37M
Depreciation and amortization 3.13M 2.29M 1.50M 0.78M 0.45M
Non operating income net other -0.30000M - -0.07700M 0.88M -
Operating income 22.94M 22.37M 10.25M 11.07M 10.37M
Other operating expenses 135.23M 107.94M 69.87M 34.41M 21.55M
Interest expense 0.44M 0.10M 0.02M 0.00500M 0.15M
Tax provision 5.15M 5.17M 1.08M 2.45M 0.66M
Interest income - - - 0.00500M 0.15M
Net interest income -0.44000M -0.09500M -0.01900M -0.00500M -0.15400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.15M 5.17M 1.08M 2.45M 0.66M
Total revenue 158.17M 130.30M 80.12M 45.47M 31.92M
Total operating expenses 103.22M 80.61M 52.46M 25.59M 15.51M
Cost of revenue 32.01M 27.32M 17.42M 8.81M 6.04M
Total other income expense net -0.74000M -0.09500M -0.09600M 0.88M -0.15400M
Discontinued operations - - - - -
Net income from continuing ops 17.05M 17.10M 9.07M 9.49M 9.55M
Net income applicable to common shares 17.05M 17.10M 9.07M 9.49M 9.55M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 122.08M 141.07M 116.47M 133.27M 72.17M
Intangible assets 7.25M 8.16M 9.07M 9.97M -
Earning assets - - - - -
Other current assets 3.61M 3.33M 0.87M 0.69M 1.38M
Total liab 86.37M 94.94M 50.11M 59.35M 15.32M
Total stockholder equity 35.71M 46.13M 66.36M 73.92M 56.85M
Deferred long term liab - - - - -
Other current liab 9.77M 5.54M 5.99M 9.82M 3.27M
Common stock 0.03M 0.03M 0.04M 0.04M 0.04M
Capital stock 0.03M 0.03M 0.04M 0.04M 0.04M
Retained earnings 29.77M 26.78M 17.05M 0.00000M 23.43M
Other liab - - 10.00M 9.70M -
Good will 20.40M 20.40M 20.40M 20.40M -
Other assets - 0.00000M 2.15M 1.30M 0.91M
Cash 39.63M 44.58M 20.14M 42.61M 39.17M
Cash and equivalents - - - - -
Total current liabilities 16.86M 18.53M 21.09M 22.87M 10.12M
Current deferred revenue - 0.63M 1.56M - -
Net debt 34.19M 31.59M 6.82M -7.52400M -31.84200M
Short term debt 4.32M 3.92M 7.94M 8.31M 2.13M
Short long term debt - - 5.33M 5.33M -
Short long term debt total 73.82M 76.17M 26.96M 35.09M 7.33M
Other stockholder equity 5.90M 19.32M 49.27M 73.88M 33.39M
Property plant equipment - - 2.17M 18.91M 1.93M
Total current assets 75.18M 87.86M 69.56M 82.69M 63.02M
Long term investments - - - - -
Net tangible assets - - 36.89M 43.55M 56.85M
Short term investments - - - - -
Net receivables 18.02M 26.84M 35.06M 28.63M 13.84M
Long term debt 58.57M 57.60M 5.29M 10.61M -
Inventory 13.92M 13.11M 13.48M 10.76M 8.63M
Accounts payable 7.09M 8.43M 5.60M 4.74M 4.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.00000M - - -
Additional paid in capital - - - - -
Common stock total equity - - 0.04M 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - 17.05M - 23.43M
Treasury stock - - - -6.51300M -3.84600M
Accumulated amortization - - - - -
Non currrent assets other 1.55M -7.74900M 0.86M 0.97M 0.67M
Deferred long term asset charges - - - - -
Non current assets total 46.90M 53.22M 46.91M 50.59M 9.15M
Capital lease obligations 15.26M 18.56M 16.33M 19.15M 7.33M
Long term debt total - - 5.29M 10.61M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.41800M -16.60600M -0.98500M -0.16000M -1.08200M
Change to liabilities 1.83M 2.89M 3.77M 0.79M 0.35M
Total cashflows from investing activities -0.41800M -16.60600M -0.98500M -0.16000M -1.08200M
Net borrowings -5.33300M 15.95M -0.05700M -0.01900M -0.50700M
Total cash from financing activities -35.79600M 13.10M 25.30M -2.23100M -3.76300M
Change to operating activities -0.18600M 0.45M -0.66500M 0.31M 0.06M
Net income 17.05M 17.10M 9.07M 9.49M 9.55M
Change in cash -22.46800M 3.44M 25.13M 3.91M 4.56M
Begin period cash flow 42.61M 39.17M 14.04M 10.13M 5.57M
End period cash flow 20.14M 42.61M 39.17M 14.04M 10.13M
Total cash from operating activities 13.75M 6.95M 0.82M 6.30M 9.41M
Issuance of capital stock - 0.00000M 25.20M 0.22M 0.18M
Depreciation 3.13M 2.29M 1.57M 0.78M 0.45M
Other cashflows from investing activities - -15.99700M - - -
Dividends paid 3.61M 0.00100M 0.00100M 2.26M 2.27M
Change to inventory -4.32000M -3.77600M -7.32300M -2.36000M -0.41400M
Change to account receivables -6.43000M -14.78100M -8.00400M -3.04200M -0.60600M
Sale purchase of stock -26.42600M -2.66700M 25.77M -0.17100M -3.43200M
Other cashflows from financing activities -0.35200M -0.25200M 0.15M -0.16000M -1.08200M
Change to netincome 1.79M 1.48M 2.63M 1.22M -0.35200M
Capital expenditures 0.42M 0.61M 0.98M 0.16M 1.08M
Change receivables -6.43000M -14.78100M -8.00400M -3.04200M -0.60600M
Cash flows other operating 0.70M 1.74M -0.90100M -0.56700M 0.27M
Exchange rate changes - - - - -
Cash and cash equivalents changes -22.46800M 3.44M 25.13M 3.91M 4.56M
Change in working capital -9.10200M -15.21500M -12.21900M -4.30400M -0.60700M
Stock based compensation 2.34M 1.63M 2.68M 0.82M 0.37M
Other non cash items 1.18M 1.29M -0.23600M -0.69500M 0.37M
Free cash flow 13.33M 6.34M -0.16700M 6.14M 8.33M

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ZYXI
Zynex Inc		 - -% - - 16.61 0.43 3.61 0.72 20.66
MCK
McKesson Corporation		 -13.47 1.43% 928.69 17.95 14.53 0.20 5.04 0.22 12.17
COR
Cencora Inc.		 -9.61 2.66% 352.19 23.39 - - -
CAH
Cardinal Health Inc		 -5.24 2.36% 217.04 166.11 14.71 0.12 16.07 0.12 19.78
HSIC
Henry Schein Inc		 -1.81 2.32% 76.29 24.12 14.04 0.74 2.50 0.95 13.33

Reports Covered

Stock Research & News

View All

Profile

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Zynex Inc

9655 Maroon Circle, Englewood, CO, United States, 80112

Key Executives

Name Title Year Born
Mr. Thomas Sandgaard Founder, Pres, CEO & Chairman 1959
Mr. Daniel J. Moorhead Chief Financial Officer 1972
Ms. Anna Lucsok Chief Operating Officer 1986
Ms. Chelle Van Burkleo VP of Sales NA
Mr. Steve Fox VP Of Sales NA
Mr. Dave Anttila Director of HR NA
Mr. Neil Friery Pres & COO of Zynex Monitoring Solutions, Inc. NA
Mr. Joachim Sandgaard Information Systems Mang. NA
Mr. Donald Gregg VP of Sales and Operations - Monitoring Solutions Division NA
Mr. Thomas Sandgaard Founder, President, CEO & Chairman 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.